Cancer News: Pancreatic
Neoadjuvant chemotherapy followed by surgery led to better outcomes in pancreatic cancer compared to upfront surgery with or without adjuvant chemotherapy.
Treating pancreatic cancer patients with oral chemotherapy drug capecitabine with gemcitabine prolonged their survival without increasing toxicity.
Scientists found that a specific protocol of chemotherapy, radiation and aggressive surgery led to better long-term survival for pancreatic cancer patients.
Scientists comparing chemoradiotherapy with chemotherapy for the treatment of locally advanced pancreatic cancer report no added survival benefit of chemoradiotherapy.
A small early-stage study reveals that an experimental immune-stimulating drug combined with chemotherapy shrunk tumors in pancreatic cancer patients.
Patients with resectable pancreatic cancer benefited from receiving at least 6 months of adjuvant chemotherapy, a new study suggests.
Pancreatic cancer surgery patients treated also with radiotherapy together with chemotherapy lived longer, a new research found.
Pancreatic cancer patients who undergo complex tumor removal operations survive longer, according to a Mayo Clinic gastrointestinal surgeon.
The combination of irinotecan liposome injection with fluorouracil and leucovorin has been approved by the FDA for the treatment of metastatic pancreatic cancer.
Patients with gastrointestinal stromal tumors may develop additional malignancies before and after their diagnosis, according to the first population-based study.
A synthetic derivative of vitamin D may improve drugs' effectiveness against this very challenging cancer, by collapsing the cells around the tumor.
Chemotherapy combined with a stereotactic ablative radiation (SABR) may be a promising treatment option for locally advanced pancreatic cancer patients.
A multicentre phase III study, with centers participating from 11 countries in North America, Europe and Australia, shows that the drug combination nab-paclitaxel and gemcitabine is more effective in the treatment of patients with advanced pancreatic cancer than gemcitabine alone, which has been the standard treatment for these patients up until now.
Obese patients with pancreatic cancer were more than twice as likely to die over an 18-to-20-year period than healthy-weight patients, researchers found.
Pancreatic cancer mortality has diverged in race-defined directions, increasing in whites and decreasing in blacks for reasons that remain unclear, investigators reported.
Cancer researchers have discovered that a protein actually promotes the growth and spread of pancreatic cancer, although it normally suppresses tumors.
Scientists believe they have discovered a new way to make chemotherapy treatment more effective for pancreatic cancer patients.
Pancreatic cancer tumors maintain a "protective wall" around themselves. Researchers have managed to enable the body's own immune cells to break it down through antibodies.
Gene mutations related to pancreatic cancer may be detected by a blood tests, without a biopsy, according to the latest research.
Metastatic pancreatic ductal adenocarcinoma patients treated with 2 different anti-cancer vaccines had improved survival compared to treatment with only 1 of them.
A small, low-cost device can help pathologists diagnose pancreatic cancer earlier and faster, as it relies on new technologies for tissue processing. It is still under development.
Scientists are building proteins that act on the tumor cell surface, and increase immune function against some tumors. Their work is still in laboratory phase.
Computed tomography (CT) scans may show how well chemotherapy will penetrate the tumor in pancreatic cancer patients, predicting the treatment’s effectiveness.
Blocking the function of an enzyme was shown to slow the growth and spread of pancreatic cancer, by preventing a protein from stimulating normal cells.
A review of 88 international studies identified a link between pancreatic cancer and diabetes, although diabetes is considered only a modest cancer risk factor.
An experimental drug for metastatic pancreatic cancer improved the overall survival rate in patients, in combination with another two drugs, in a clinical trial.
Patients with pancreatic cancer have a different and distinct profile of specific bacteria in their saliva, even compared to patients with other cancers.